

ABSTRACT

The present invention relates to a combination therapy for effectively preventing or treating obesity. More specifically, the objective of the present invention is to effectively prevent or treat obesity through a synergistic effect obtained when a melanocortin-4
5 receptor (MC4R) agonist and a glucagon-like peptide-1 (GLP-1) receptor agonist are administered in combination.